Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Marchiafava Bignami disease is defined by characteristic demyelination of the corpus callosum (erosion of the protective covering of nerve fibers joining the 2 hemispheres of the brain). The disease seems to most often affect severe and chronic alcoholics in their middle or late adult life. Early symptoms may include depression, paranoia, psychosis, or dementia. Seizures are common, and hemiparesis, aphasia, abnormal movements, and ataxia may sometimesprogress to coma and/or death. The cause of Marchiafava Bignami disease, including the potential role of nutritional deficiency, remains unknown. Improvement and recovery of some individuals has been reported. Treatment focuses on nutritional support and rehabilitation from alcoholism.
Biomarker and diagnostic research for Marchiafava-Bignami disease has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Marchiafava-Bignami disease.
36 publications have been identified in PubMed for Marchiafava-Bignami disease. Research spans Case Report / Case Series (72%), Other (17%), and Review / Meta-Analysis (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 26 | 72% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 12:12 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Marchiafava-Bignami disease
6 |
17% |
Research summaries | 3 | 8% |
Testing and diagnosis research | 1 | 3% |
Ramos D (2026). [PMID: 41732620](https://pubmed.ncbi.nlm.nih.gov/41732620/). *Cureus*. [Case Report / Case Series]
Michiwaki Y (2026). [PMID: 41783222](https://pubmed.ncbi.nlm.nih.gov/41783222/). *Surg Neurol Int*. [Case Report / Case Series]
Zhou Z (2026). [PMID: 41510871](https://pubmed.ncbi.nlm.nih.gov/41510871/). *Neurol India*. [Case Report / Case Series]
Zhang J (2026). [PMID: 41930251](https://pubmed.ncbi.nlm.nih.gov/41930251/). *Front Mol Biosci*. [Case Report / Case Series]
Tian TY (2026). [PMID: 30252263](https://pubmed.ncbi.nlm.nih.gov/30252263/). *Unknown Journal*. [Other]
Nojima T (2026). [PMID: 41584392](https://pubmed.ncbi.nlm.nih.gov/41584392/). *Clin Case Rep*. [Case Report / Case Series]
Chen Y (2026). [PMID: 42183947](https://pubmed.ncbi.nlm.nih.gov/42183947/). *Neurol Sci*. [Case Report / Case Series]
Wu BP (2026). [PMID: 41609123](https://pubmed.ncbi.nlm.nih.gov/41609123/). *Acta Neurol Taiwan*. [Case Report / Case Series]
Kawamura M (2025). [PMID: 41355088](https://pubmed.ncbi.nlm.nih.gov/41355088/). *Brain Nerve*. [Other]
Canbeldek L (2025). [PMID: 40581781](https://pubmed.ncbi.nlm.nih.gov/40581781/). *J Neuropathol Exp Neurol*. [Case Report / Case Series]
AI-curated news mentioning Marchiafava-Bignami disease
Updated Aug 26, 2026
A recent case study highlights Marchiafava-Bignami disease in an alcoholic patient presenting with reduced consciousness and muscle paratonia. This research adds to the understanding of the disease's clinical manifestations.